Differential protection of normal and malignant human myeloid progenitors (CFU-GM) from ara-C toxicity using cycloheximide

C. A. Slapak, R. L. Fine, Carol M Richman

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Cycloheximide, a reversible protein sythesis inhibitor, is thought to block DNA replication in normal cells by preventing synthesis of a labile protein. In animal systems, cycloheximide protects normal cells from cytotoxic S-phase specific agents, such as cytosine arabinoside (Ara-C). Malignant cells appear not to be susceptible to cycloheximide-induced cycle arrest and, subsequently, may not be protected from Ara-C cytotoxicity. The effect of cycloheximide on granulocyte/macrophage progenitors (CFU-GM) after in vitro Ara-C exposure was examined using normal human bone marrow, malignant progenitors from patients with chronic myelogenous leukemia (CML), and clonogenic cells from the human acute nonlymphocytic leukemia cell lines HL-60 and KG-1. Mononuclear or clonogenic cells were incubated for one hour with cycloheximide, followed by the addition, for three or 17 hours, of Ara-C before being plated in a methylcellulose culture system. CFU-GM survival was significantly increased if normal cells were treated with cycloheximide before Ara-C exposure. Similar cycloheximide pretreatment of CML progenitors and clonogenic HL-60 and KG-1 cells failed to protect CFU-GM from Ara-C-induced cytotoxicity.

Original languageEnglish (US)
Pages (from-to)830-834
Number of pages5
JournalBlood
Volume66
Issue number4
StatePublished - 1985
Externally publishedYes

Fingerprint

Granulocyte-Macrophage Progenitor Cells
Cytarabine
Cycloheximide
Toxicity
Cytotoxicity
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Methylcellulose
Macrophages
DNA Replication
S Phase
Acute Myeloid Leukemia
Bone
Animals
Proteins
Bone Marrow
Cells
Cell Line
DNA

ASJC Scopus subject areas

  • Hematology

Cite this

Differential protection of normal and malignant human myeloid progenitors (CFU-GM) from ara-C toxicity using cycloheximide. / Slapak, C. A.; Fine, R. L.; Richman, Carol M.

In: Blood, Vol. 66, No. 4, 1985, p. 830-834.

Research output: Contribution to journalArticle

@article{e1a7d8ab15de4aa5afee5d576448f59f,
title = "Differential protection of normal and malignant human myeloid progenitors (CFU-GM) from ara-C toxicity using cycloheximide",
abstract = "Cycloheximide, a reversible protein sythesis inhibitor, is thought to block DNA replication in normal cells by preventing synthesis of a labile protein. In animal systems, cycloheximide protects normal cells from cytotoxic S-phase specific agents, such as cytosine arabinoside (Ara-C). Malignant cells appear not to be susceptible to cycloheximide-induced cycle arrest and, subsequently, may not be protected from Ara-C cytotoxicity. The effect of cycloheximide on granulocyte/macrophage progenitors (CFU-GM) after in vitro Ara-C exposure was examined using normal human bone marrow, malignant progenitors from patients with chronic myelogenous leukemia (CML), and clonogenic cells from the human acute nonlymphocytic leukemia cell lines HL-60 and KG-1. Mononuclear or clonogenic cells were incubated for one hour with cycloheximide, followed by the addition, for three or 17 hours, of Ara-C before being plated in a methylcellulose culture system. CFU-GM survival was significantly increased if normal cells were treated with cycloheximide before Ara-C exposure. Similar cycloheximide pretreatment of CML progenitors and clonogenic HL-60 and KG-1 cells failed to protect CFU-GM from Ara-C-induced cytotoxicity.",
author = "Slapak, {C. A.} and Fine, {R. L.} and Richman, {Carol M}",
year = "1985",
language = "English (US)",
volume = "66",
pages = "830--834",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Differential protection of normal and malignant human myeloid progenitors (CFU-GM) from ara-C toxicity using cycloheximide

AU - Slapak, C. A.

AU - Fine, R. L.

AU - Richman, Carol M

PY - 1985

Y1 - 1985

N2 - Cycloheximide, a reversible protein sythesis inhibitor, is thought to block DNA replication in normal cells by preventing synthesis of a labile protein. In animal systems, cycloheximide protects normal cells from cytotoxic S-phase specific agents, such as cytosine arabinoside (Ara-C). Malignant cells appear not to be susceptible to cycloheximide-induced cycle arrest and, subsequently, may not be protected from Ara-C cytotoxicity. The effect of cycloheximide on granulocyte/macrophage progenitors (CFU-GM) after in vitro Ara-C exposure was examined using normal human bone marrow, malignant progenitors from patients with chronic myelogenous leukemia (CML), and clonogenic cells from the human acute nonlymphocytic leukemia cell lines HL-60 and KG-1. Mononuclear or clonogenic cells were incubated for one hour with cycloheximide, followed by the addition, for three or 17 hours, of Ara-C before being plated in a methylcellulose culture system. CFU-GM survival was significantly increased if normal cells were treated with cycloheximide before Ara-C exposure. Similar cycloheximide pretreatment of CML progenitors and clonogenic HL-60 and KG-1 cells failed to protect CFU-GM from Ara-C-induced cytotoxicity.

AB - Cycloheximide, a reversible protein sythesis inhibitor, is thought to block DNA replication in normal cells by preventing synthesis of a labile protein. In animal systems, cycloheximide protects normal cells from cytotoxic S-phase specific agents, such as cytosine arabinoside (Ara-C). Malignant cells appear not to be susceptible to cycloheximide-induced cycle arrest and, subsequently, may not be protected from Ara-C cytotoxicity. The effect of cycloheximide on granulocyte/macrophage progenitors (CFU-GM) after in vitro Ara-C exposure was examined using normal human bone marrow, malignant progenitors from patients with chronic myelogenous leukemia (CML), and clonogenic cells from the human acute nonlymphocytic leukemia cell lines HL-60 and KG-1. Mononuclear or clonogenic cells were incubated for one hour with cycloheximide, followed by the addition, for three or 17 hours, of Ara-C before being plated in a methylcellulose culture system. CFU-GM survival was significantly increased if normal cells were treated with cycloheximide before Ara-C exposure. Similar cycloheximide pretreatment of CML progenitors and clonogenic HL-60 and KG-1 cells failed to protect CFU-GM from Ara-C-induced cytotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=0021966834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021966834&partnerID=8YFLogxK

M3 - Article

C2 - 3862435

AN - SCOPUS:0021966834

VL - 66

SP - 830

EP - 834

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -